The gap in drug development between where NIH-funded research typically leaves off and industry development begins has become known as the “valley of death.” The Blueprint Neurotherapeutics Network will span this region of the drug development pipeline, providing funding and research services to advance promising hit compounds through lead optimization, candidate selection, preclinical safety, and phase I clinical testing.